ReviewiScience2026
Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM), a type of hematologic malignancy, is characterized by the uncontrolled proliferation of plasma cells in the bone marrow. There have been significant challenges in treating MM due to factors such as relapse, resistance, and antigen escape. Over the past decade, the treatment algorithm has shifted from traditional chemotherapy to immune-based therapies and quadruplet induction regimens. To our knowledge, no published review has yet provided an integrated analysis of current FDA-approved CAR-T therapies and quadruplet therapy regimens for MM. This review examines the mechanistic rationale of combining CAR-T and quadruplet therapy by modulation of the immune microenvironment. Based on findings from recent clinical trials, this review assesses the potential synergistic benefit of combining these approaches to improve long-term outcomes in MM patients. Thereafter, the persistent limitations and areas for further research are highlighted, along with actionable next steps to advance these therapies and improve patient outcomes while addressing real-world barriers that require implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.